Articles tagged with Drug Therapy
Researchers at the University of Pennsylvania have identified a key factor in T-cell leukemia disease relapse - genome refolding. The study found that cancer cells adapt to targeted therapy by changing the folding of their genome, driven by transcription factor repositioning.
Researchers found that Neem bark components target a wide range of viral proteins, suggesting its potential as an antiviral agent against emerging coronavirus variants. The study showed the bark extract was effective in reducing virus replication and spread in SARS-CoV-2 human lung cells.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
The AAN has issued an evidence-in-focus article on aducanumab, a treatment for early changes in the brain associated with Alzheimer's disease. The article notes that while aducanumab reduces amyloid plaques, its effects on symptoms and side effects are unclear.
A new study found that cashew stem bark extract inhibits abnormal gut motility associated with diarrhea, revealing a potential low-cost remedy for treating and managing the condition. The extract's mechanism of action involves blocking muscarinic acetylcholine receptors responsible for gastrointestinal motility.
Researchers from Tel Aviv University found that hyperbaric oxygen therapy (HBOT) relieves PTSD symptoms in treatment-resistant veterans, improving brain function and microstructure. The breakthrough study provides new hope for PTSD sufferers, offering an objective diagnostic tool and potential long-term improvements.
Researchers have identified a key brain protein to target for new customized drug therapies treating adverse symptoms of developmental disorder subtypes. The study found that mutations in ARHGEF9 lead to intellectual disability through impaired α2 subunit function, which is a central hub for many neurological symptoms.
A new study from the University of Copenhagen has made significant breakthroughs in treating Parkinson's disease by targeting specific neurons in the brainstem. By stimulating excitatory neurons in the caudal area of the pedunculopontine nucleus, researchers were able to restore normal walking function in mice with Parkinson's symptoms.
Researchers at UC San Diego have made a groundbreaking discovery about the role of fibroblasts, or fat cells, in controlling bacteria and developing acne. These findings could lead to more targeted treatment options for acne, which affects up to 50 million Americans each year.
A small study found statistically significant improvements in various symptoms, including fatigue and chest discomfort, after EECP therapy in long COVID patients. Researchers believe this is the most plausible explanation for the benefits derived from EECP and its link to long COVID.
Researchers at NTU Singapore have developed a new method to generate sulphur pharmacophores, which are crucial for drug discovery. The method uses a catalyst called pentanidium and can produce multiple variations of pharmacophores, making the process more efficient and fruitful.
Researchers at the University of Toronto have identified hundreds of new proteins associated with cystic fibrosis, including those that interact with the CFTR protein. These discoveries may shed light on why some patients respond better than others to current therapies.
A new class of compounds improves insulin secretion and sensitivity, lowering blood sugar levels and reducing liver fat buildup in mice with diabetes. The study's findings offer hope for developing new treatments for cardiovascular disease and metabolic syndrome.
Researchers at Lancaster University have identified a genetic change that impacts insulin signaling and glucose metabolism in the brain, which may lead to effective drug treatments for autism. The study found that individuals with a specific DNA deletion are more likely to develop neurodevelopmental disorders, including autism.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
Researchers at Johns Hopkins Medicine found that certain stem cells have built-in tracers made of sugars that can track their movement in living tissues. The discovery could streamline and advance restorative research for diseases of the brain.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
A groundbreaking genome-wide association study identified 123 genetic regions linked to migraine risk, including two specific genes targeted by recently developed drugs. The study provides insight into the biological basis of migraine and its subtypes, paving the way for new treatments.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A recent University at Buffalo-led study found that nearly 1 in 7 COVID patients in ICU experienced severe bleeding when given full-dose blood thinners. The research compared the safety and effectiveness of two blood clot treatment strategies, finding that a smaller dose was equally effective but carried less bleeding risk.
A study led by Clemson University geneticist Allison Hickman has identified 11 high-priority genes associated with uterine cancer. These genes are potential targets for drug therapies, offering new hope for effective treatment options.
Researchers report successful treatment of two young infants with PROS using breast cancer drug alpelisib, inducing rapid and significant clinical improvement in symptoms. The treatment was well-tolerated and showed promising results, supporting the use of low-dose alpelisib in these patients.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Researchers have identified two new compounds that can inhibit the replication of human herpesviruses by targeting specific enzymes. This breakthrough offers new opportunities for developing agents against herpesviruses, which are currently difficult to treat effectively.
A phase 3 clinical trial is underway to test the safety and efficacy of jacifusen, an experimental drug that lowered levels of toxic protein FUS in a patient with juvenile ALS. The trial aims to determine if the drug can slow disease progression in symptomatic patients.
Scientists have identified natural nano-bubbles containing the ACE2 protein in COVID-19 patients' blood, which can block infection from broad strains of SARS-CoV-2 virus. These nano bubbles serve as a decoy to lure the virus away from cells, preventing infection.
Researchers developed a gene therapy called Targeted Augmentation of Nuclear Gene Output (TANGO), which boosts SCN1A protein production in brain cells. The treatment restored normal cell function and reduced seizures in lab mice with Dravet syndrome, offering hope for the first direct treatment of the fundamental cause.
Researchers found that a third of patients with wet age-related macular degeneration can safely stop eye injection therapy without further vision loss. Patients who stopped treatment showed better visual acuity, gain of vision, and less fluid in their retina compared to those requiring continued injections.
A mathematical model developed by researchers at Massachusetts General Hospital has identified biological markers that can predict treatment responses in COVID-19 patients. The model reveals differences in patient characteristics and response to therapy, enabling clinicians to provide optimal care for diverse patients.
The Cardiovascular Research Foundation (CRF) will host THT 2022 from February 1-2, 2022. The conference features new and emerging treatments for heart failure, including transcatheter approaches and innovative monitoring strategies.
A new study found that oral bisphosphonates risedronate and alendronate equally protect against hip fractures during a 2-year drug holiday. However, the risk increases slightly for those taking a break from risedronate.
Researchers at Penn Medicine have discovered a new method to prevent the body's proteins from attacking treatment-carrying nanoparticles, allowing for more effective delivery of therapies. By coating nanoparticles with natural suppressors of complement activation, such as Factor I, the team has shown improved protection against immune ...
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
Researchers at Penn Medicine have developed a structural blueprint for nanoparticles that can target and deliver treatment to white blood cells, such as neutrophils, that contribute to acute lung inflammation. The findings represent a significant step in understanding the condition and function of the immune system.
A new study published in the Canadian Journal of Cardiology found that frail patients with atrial fibrillation are under-prescribed for direct oral anticoagulants (DOACs), a safer alternative to traditional warfarin treatment. Despite needing DOACs most, these patients are less likely to receive them than non-frail patients.
Researchers at Tel Aviv University successfully treated autism in animal models with medical cannabis oil, improving behavioral and biochemical parameters. The treatment showed significant improvement in compulsive and anxious behaviors, and a decrease in the concentration of the arousing neurotransmitter glutamate.
Scientists have found that the gene PBK is overexpressed in pulmonary hypertension, causing excessive cell proliferation and thickening of pulmonary artery walls. They are now exploring PBK inhibitors to reduce cell proliferation and improve heart and lung function.
Researchers have discovered a nanoparticle therapeutic that enhances cancer immunotherapy and treats malignant pleural effusion. The treatment targets the immune system to recognize and eliminate cancer cells, improving survival rates and quality of life for patients.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
A case series of 10 children with severe epilepsy found that whole plant medicinal cannabis reduced monthly seizure frequency by an average of 86%. The study suggests that whole plant products may be more effective than CBD products in treating childhood-onset severe treatment-resistant epilepsy.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.
An experimental drug called NAP has been found effective in treating a broad spectrum of symptoms related to autism, intellectual disability, and Alzheimer's disease. Researchers discovered that NAP normalizes brain function in mice modeling ADNP syndrome, a rare disorder linked to these conditions.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
Researchers identified a mechanism for how genetically defective cells mutate to survive stressful situations, such as drug treatment. Understanding this resistance mechanism could lead to the development of new strategies to delay or prevent cancer drug resistance.
A new meta-analysis published in the European Journal of Preventive Cardiology suggests that Sodium-glucose co-transporter-2 (SGLT2) inhibitors can improve outcomes for heart failure patients with preserved ejection fraction. The medication has been shown to reduce the risk of death from heart-related causes and hospitalization by 22%.
Researchers discovered that eliminating α-endosulfine (ENSA) or blocking its function reduces brain changes and improves memory in mice. ENSA blocks a potassium channel, which, when blocked, combats excess ENSA levels associated with Alzheimer's disease.
Researchers compared genetic expression profiles of canine acanthomatous ameloblastoma and human oral tumor ameloblastoma, finding similarities in molecular mutations. The study lays groundwork for potential translational medicine, as the dog model may represent a useful clinical model of the disease.
A study published in the American Journal of Respiratory and Critical Care Medicine found that prostacyclin treatment reduced damage to vital organs and halved mortality rates among critically ill Covid-19 patients. The research team hopes to investigate larger patient populations in future studies.
Researchers at University of Technology Sydney identified microRNA-21 as a potential therapeutic target for chronic obstructive pulmonary disease (COPD). Inhibition of microRNA-21 using antagomir-21 reduced inflammation and improved lung capacity in experimental models.
Researchers have discovered a new therapeutic approach that prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state. The drug C26 activates NR2F1, a protein that can induce cancer cell dormancy and prevent recurrence and metastasis.
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
A recent study by James Godwin, Ph.D. has identified the liver as a primary reservoir for pro-regenerative macrophages essential to limb regeneration in axolotls. The research paves the way for regenerative medicine therapies in humans, potentially treating diseases like heart and lung disease with scar-free healing.
A novel gene therapy has shown sustained expression of clotting factor VIII, leading to a reduction or complete elimination of bleeding events in patients with hemophilia A. The trial demonstrated improved production of coagulation factor VIII over prolonged periods.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
Researchers found that candesartan reduces accumulation of extracellular matrix proteins and normalizes blood flow in mice with hereditary cerebral small vessel disease. The study suggests a potential new treatment avenue for age-related cerebral arteriopathy.
A UCalgary study found that the steroid dexamethasone alters immune cell function in a sex-dependent manner, benefiting male patients but providing little to no benefit for females. The researchers' findings suggest that current treatments may only be effective for half the population.